Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction

Collapse authors list.
Sharp, Andrew ORCID: 0000-0003-3396-7464, Cornforth, Christine, Jackson, Richard, Harrold, Jane ORCID: 0000-0002-9281-1446, Turner, Mark A ORCID: 0000-0002-5299-8656, Kenny, Louise ORCID: 0000-0002-9011-759X, Baker, Philip N, Johnstone, Edward D, Khalil, Asma, von Dadelszen, Peter et al (show 2 more authors) , Papageorghiou, Aris T and Alfirevic, Zarko ORCID: 0000-0001-9276-518X (2019) Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction. LANCET CHILD & ADOLESCENT HEALTH, 3 (3). E2-E3.

	Text Commentary for Lancet FINAL reviewed and edited clean.docx - Author Accepted Manuscript Download (32kB)
	Text Commentary for Lancet FINAL.docx - Author Accepted Manuscript Download (32kB)

Item Type:	Article
Uncontrolled Keywords:	Humans, Fetal Growth Retardation, Pregnancy, Infant, Newborn, Female, Randomized Controlled Trials as Topic, Phosphodiesterase 5 Inhibitors, Sildenafil Citrate, United Kingdom
Depositing User:	Symplectic Admin
Date Deposited:	21 Aug 2020 07:18
Last Modified:	18 Jan 2023 23:39
DOI:	10.1016/S2352-4642(19)30020-3
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3095117

Available Versions of this Item

• Review of mortality from the STRIDER UK trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction. (deposited 17 Jan 2019 08:21)
  • Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction. (deposited 21 Aug 2020 07:18) [Currently Displayed]